Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Modelo predictivo del riesgo de infección y rechazo después del trasplante renal basado en la combinadición de parámetros clínicos y biomarcadores.

IP: Francesc Moreso Mateos
Collaborators: Romina Dieli Crimi, Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa, Nestor Gabriel Toapanta Gaibor
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI18/01832
Duration: 01/01/2019 - 31/12/2022

Relación entre los niveles de tacrolimus y/o dosis de micofenolato y la modulación de los genes de rechazo en biopsias de seguimiento del aloinjerto renal

IP: Daniel Serón Micas
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI18/01704
Duration: 01/01/2019 - 31/12/2021

Apolipoproteína AIb como biomarcador y diana terapéutica de la glomeruloesclerosis segmentaria y focal idiopática (GESF)

IP: Joan López Hellin
Collaborators: José Antonio Arranz Amo, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Instituto de Salud Carlos III
Funding: 88935
Reference: PI14/00275
Duration: 01/01/2015 - 30/06/2018

Promoting regeneration versus tubulointerstitial fibrosis in progressive renal disease: Novel molecular pathways

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO-2012-01
Duration: 06/10/2012 - 05/10/2014

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

Eva Guisuraga San Miguel

Eva Guisuraga San Miguel

Gestió i Administració
Talent Attraction and Acquisition Unit
Human Resources Directorate
Read more
Maria Jose Herrero Mata

Maria Jose Herrero Mata

Postdoctoral researcher
Transfusional Medicine
Read more
Empar Francesca Moreno Penadés

Empar Francesca Moreno Penadés

Predoctoral researcher
Liver Diseases
Read more
Jorge Hernández Vara

Jorge Hernández Vara

Main researcher
Neurodegenerative Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.